Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.70
-0.2000-2.53%
Post-market: 7.800.1000+1.30%19:30 EDT
Volume:4.07M
Turnover:31.33M
Market Cap:697.34M
PE:-3.19
High:8.02
Open:7.95
Low:7.52
Close:7.90
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:2.44
T/O Rate:5.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:13.95
PE(LYR):-2.55

Loading ...

VS-7375 Demonstrates Clinical Activity With a Favorable Safety and Tolerability Profile in Target-D 101 Phase 1/2 Clinical Trial in Patients With Advanced Kras G12d-Mutated Solid Tumors

THOMSON REUTERS
·
Jun 24

Verastem - VS-7375 Safety Profile Mainly Low-Grade Gi Events That Decrease After Cycle 1

THOMSON REUTERS
·
Jun 24

Verastem price target lowered to $8 from $15 at Jefferies

TIPRANKS
·
Jun 24

Verastem Is Maintained at Buy by Jefferies

Dow Jones
·
Jun 23

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron

Reuters
·
Jun 17

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and ClearPoint Neuro (CLPT)

TIPRANKS
·
Jun 17

Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial

TIPRANKS
·
Jun 17

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

TIPRANKS
·
Jun 17

BUZZ-Verastem rises as combo therapy shows early benefit in pancreatic cancer

Reuters
·
Jun 17

Verastem says RAMP 205 trial shows 52% response rate for avutometinib-defactinib combo in first-line metastatic pancreatic cancer

Reuters
·
Jun 17

Verastem Oncology Announces Positive Updated Results From Ramp 205 Evaluating Avutometinib Plus Defactinib in Combination With Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jun 17

Verastem - Reports 86% Overall Survival Rate at 6 Months as of June 5, 2026

THOMSON REUTERS
·
Jun 17

Verastem - No New Safety Signals Observed in Ramp 205 Trial

THOMSON REUTERS
·
Jun 17

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

TIPRANKS
·
Jun 17

Verastem Oncology Doses First Patient in Target-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral Kras G12d (on/off) Inhibitor for Kras G12d-Mutated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jun 17

Verastem Oncology updates Phase 1/2 TARGET-D 101 data for KRAS G12D inhibitor VS-7375

Reuters
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)

TIPRANKS
·
Jun 09

Verastem's Lung Cancer Drug Gets FDA Fast Track Designation

MT Newswires Live
·
Jun 04

BUZZ-Verastem rises after FDA grants fast-track status for cancer drug

Reuters
·
Jun 04

BRIEF-Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC

Reuters
·
Jun 04